Access to innovative therapies in pediatric oncology: Report of the nationwide experience in Canada.

"CONFLICT OF INTEREST STATEMENT JW: Research funding (institutional): Novartis, Daiichi Sankyo; Honoraria: Jazz, Servier. DM: Consultancy for ymAbs Therapeutics, Clarity Pharmaceuticals, RayzeBio, Regeneron and Oncoheroes Biosciences. Travel expenses Abbvie. Speaker fees from Takeda Israel Ltd. All other authors (SJ, GRR, RJD, MIV, VAL, LP, APZ, CG, RS, THT, LSA, JB, PM, SA, CP, SAG, AD, SCG) have no conflicts of interest to declare."

"FUNDING INFORMATION Sandra Judd in the role of National Pediatric Oncology Drug Access Navigator has been supported by the PRecision Oncology For Young peopLE (PROFYLE) Program with funding from the Terry Fox Research Institute, Team Finn Foundation, and the Garron Family Cancer Centre. Gabriel Revon‐Riviere has been supported by the Atrium/CMCC Hold‘em for Life Oncology Fellowship. James A Whitlock is supported in part by the Women‘s Auxiliary Millennium Chair in Hematology/Oncology at the Hospital for Sick Children. This research did not receive any specific grant from funding agencies in the public, commercial, or not‐for‐profit sectors."